Multi-SNP Analysis of MHC Region

Remarkable Conservation of HLA-A1-B8-DR3 Haplotype

  1. Theresa A. Aly1,
  2. Elise Eller1,
  3. Akane Ide1,
  4. Katherine Gowan2,
  5. Sunanda R. Babu1,
  6. Henry A. Erlich3,
  7. Marian J. Rewers4,
  8. George S. Eisenbarth1 and
  9. Pamela R. Fain12
  1. 1Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Aurora, Colorado
  2. 2Human Medical Genetics Program Aurora, Colorado
  3. 3Roche Molecular Systems, Berkeley, California
  4. 4Department of Preventive Medicine and Biometrics, University of Colorado at Denver and Health Sciences Center, Denver, Colorado
  1. Address correspondence and reprint requests to Pamela R. Fain PhD, Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Mail Stop B140, P.O. Box 6511, Aurora, CO 80045-6511. E-mail: pam.fain{at}UCHSC.edu

Abstract

Technology has become available to cost-effectively analyze thousands of single nucleotide polymorphisms (SNPs). We recently confirmed by genotyping a small series of class I alleles and microsatellite markers that the extended haplotype HLA-A1-B8-DR3 (8.1 AH) at the major histocompatibility complex (MHC) is a common and conserved haplotype. To further evaluate the region of conservation of the DR3 haplotypes, we genotyped 31 8.1 AHs and 29 other DR3 haplotypes with a panel of 656 SNPs spanning 4.8 Mb in the MHC region. This multi-SNP evaluation revealed a 2.9-Mb region that was essentially invariable for all 31 8.1 AHs. The 31 8.1 AHs were >99.9% identical for 384 consecutive SNPs of the 656 SNPs analyzed. Future association studies of MHC-linked susceptibility to type 1 diabetes will need to account for the extensive conservation of the 8.1 AH, since individuals who carry this haplotype provide no information about the differential effects of the alleles that are present on this haplotype.

More than 20 years ago, analysis of polymorphisms of complement genes, such as the 21-hydroxylase gene and alleles of class I and II major histocompatibility complex (MHC) genes, identified a number of MHC haplotypes that were termed “conserved extended haplotypes” or “ancestral haplotypes” (14). A Basque haplotype studied in U.S. French-Canadian populations with the HLA A30, Cw5, B18, BfF1, C4F, C4s°, DR3 haplotype was associated with diabetes susceptibility, and more recent studies have confirmed increased risk associated with this haplotype (5). The HLA-A1-B8-DR3 haplotype (8.1 AH) is one of the most common extended DR3 haplotypes, with a northern-European frequency of ∼10%. The 8.1 AH consists of the HLA-A1, HLA-Cw7, HLA-B8, MICA-5.1, DR3, and DQ2 alleles (6) and has been sequenced by Stewart et al. (7). It has been associated with multiple immunological diseases, such as type 1 diabetes, celiac disease, systemic lupus erythematosus, common variable immunodeficiency, myasthenia gravis, and accelerated HIV disease (8,9,10). However, a recent study has reported that the 8.1 AH is not more diabetogenic compared with other DR3 haplotypes (6).

With the sequencing of the genome, the development of single nucleotide polymorphism (SNP) databases and haplotype maps, software to analyze haplotype blocks, and finally development of cost-effective large-scale SNP typing reagents, detailed multi-SNP analysis of the MHC region is now feasible. In this study, the analysis of multiple SNPs was necessary to describe the amount of conservation of the 8.1 AH or the proportion of alleles that were identical between 8.1 AHs. The basic scientific question we explored was how long and how conserved is the extended 8.1 AH? With our analysis of 656 SNPs of 31 8.1 AHs, we describe the 8.1 AH as having a remarkably long region (2.9 Mb) of >99.9% conservation.

RESEARCH DESIGN AND METHODS

In the ongoing prospective Diabetes Autoimmunity Study of the Young (DAISY), participants (most with Caucasian and Hispanic ancestry) were HLA typed and stratified into groups by family history of type 1A diabetes. Subgroups of DAISY children were enrolled for prospective follow-up of development of anti-islet autoantibodies and diabetes. DNA samples from DAISY families, including children and parents with and without type 1 diabetes, were genotyped at the HLA-A, -B, -DRB1, and -DQB1 loci with sequence-specific oligonucleotide genotyping as previously described (11). The MICA microsatellite marker was genotyped using fluorescence-based methods as previously described (12). DNA from 45 of these families (143 individuals) was analyzed with Illumina multiplex technology. Twenty of the individuals analyzed in these 45 families had type 1 diabetes, 10 additional nondiabetic individuals were persistently positive for anti-islet autoantibodies, and 117 were unaffected.

Selection of SNPs.

First, all SNPs located in or within 6 kb of the coding regions of high-priority genes with a known or suspected autoimmune function were selected. For genes of lower priority, a single representative SNP was selected. In addition, all coding SNPs, regardless of gene priority, were included. Finally, SNPs were selected to break down any interval >30 kb. All chosen SNPs had minor allele frequencies of at least 0.10 and were validated with at least double-hit validation. A total of 656 SNPs spanning 4.8 Mb in the MHC region were included and successfully genotyped by Illumina (Fig. 1). The mean inter-SNP interval size was 6,309 bp (range 61–29,937 bp). Forty-nine percent of the intervals between adjacent SNPs were <2,000 bp.

Statistical analysis.

SNP results for 13 homozygous DR3-DQ2 individuals and 11 homozygous DR4-DQ8 individuals were isolated, and all heterozygous loci were highlighted to illustrate regions of lower conservation. The Illumina genotype results were processed with the program PedCheck to assure that there was a Mendelian pattern of genotype inheritance for each family, and Merlin was used to determine the phase of the haplotypes. DR3 haplotypes (n = 60) from the parents were stratified into the 8.1 AH group (n = 31); the HLA-B8-DR3, non-A1 group (n = 16); and the HLA-DR3, non-B8 group (n = 13). The 60 DR3 haplotypes were analyzed to determine the allelic frequencies at each of the 656 SNPs, and a consensus sequence of the more common or major alleles was established. Minor alleles along each individual DR3 haplotype were highlighted. Major alleles for this population and alleles that were not called due to ambiguities or unknown phase were not highlighted.

RESULTS

Five replicate DNA samples were genotyped for the 656 SNPs to assess the reproducibility of SNP allele calls, including one blind replicate that was not included in routine error screening analysis by Illumina. All called SNPs were identical for all five pairs of replicate samples with a reproducibility of 100%.

Of 13 DR3-DQ2/DR3-DQ2 individuals evaluated for homozygosity at the SNP loci, three were homozygous at HLA-B (B8/B8) and HLA-A (A1/A1), inheriting the 8.1 AH. These three individuals (left three columns in Fig. 2) were homozygous for 356 consecutive SNPs, without exception, spanning 2.9 Mb from rs362536 to rs3135391 (from nucleotide 29,634,918 to 32,518,964). A shorter but still dramatic region of conservation was present for the DR3-DQ2 homozygous individuals in whom one or more haplotype lacked HLA-A1. DR3-DQ2 homozygous individuals with a haplotype without HLA-B8 lacked the large region of conservation. Four DRB1*0401-DQ8 homozygous individuals had a short region of much less conservation surrounding the class II loci compared with the 8.1 AH homozygotes, similar to the remaining seven DR4-DQ8 individuals (Fig. 2).

Of the total 60 DR3 haplotypes from unrelated individuals, the HLA-A1 and -B8 alleles were present on 31 haplotypes. Similar to the analysis of the 8.1 AH homozygotes, the total group of 8.1 AHs had identical alleles for 98% of 384 consecutive SNPs (378 of 384), extending from rs1611165 to rs11759565 and defining a 2.9-Mb region of conservation from nucleotide 29,900,092 to 32,825,923, ∼100 kb telomeric of HLA-A to 165 kb centromeric of DRB1 (arrows in Fig. 1). This region was >99.9% conserved, with only 9 variant alleles of the 10,768 alleles identified for the 384 SNPs in the 31 8.1 AHs [(10,768–10,769)/10,768 = 99.9%]. The conserved region stretched to the telomeric limit of the 4.8-Mb HLA region analyzed for 23 of the 31 haplotypes. For the entire MHC panel of 656 SNPs, the 31 8.1 AHs were significantly more conserved than the 29 other DR3 haplotypes analyzed. (Minor to major alleles in 8.1 AHs was 1,146 of 17,124 vs. 5,228 of 16,285 in the other DR3 haplotypes, χ2 = 2,385, P < 0.0001.)

The group of HLA-B8-DR3, non-A1 haplotypes generally had a smaller region of conservation than the 8.1 AHs, with one of the haplotypes having much more variability (right column in the HLA-B8-DR3, non-A1 panel of Fig. 3). In contrast, no extended region of conservation was found with analysis of haplotypes with A1 but without DR3 alleles, although a non-DR3 (DR4) HLA-A1-B8 haplotype had a conserved region surrounding the HLA-A1-B8 loci (seven right columns in Fig. 3). DP alleles, located 33.1 Mb from the telomere, were ∼325 kb outside of the region of extensive conservation of the 8.1 AH (Fig. 3), consistent with reports of one or more recombination hotspots centromeric to DQB1 (13,14).

After stratifying the 60 DR3 haplotypes by affected status (26 diabetic and anti–islet autoantibody–positive haplotypes vs. 34 unaffected haplotypes), none of the SNPs were associated with diabetic autoimmunity (Fig. 3). There was no difference in the conserved 8.1 AHs between the nine diabetic haplotypes, the five nondiabetic autoantibody-positive haplotypes, and the 17 autoantibody-negative haplotypes. The alleles for each haplotype of each of the 147 individuals analyzed for this study are available in the online appendix (available at http://diabetes.diabetesjournals.org).

DISCUSSION

Our data show that 8.1 AH haplotypes have >99.9% conservation of alleles spanning a 2.9-Mb region of the MHC (equating to <0.1% allelic diversity). The conserved region reaches the telomeric limits of our SNP map for the majority of these haplotypes. The current results are based on three A1-B8-DR3 homozygotes together with 25 other A1-B8-DR3 haplotypes that were reconstructed from family data.

In contrast to SNPs, short tandem repeats (STRs) generally have a higher mutation rate. Thus, when Vorchevsky et al. (15) analyzed a 1.5-Mb region between the RING3 and HLA-B genes of the 8.1 AH with 23 STRs, they found an allelic diversity of 1.9%, suggesting low allelic variability at the STR loci, though not as low as the remarkable conservation of SNPs observed in the current study (1.9 vs. <0.1% allelic diversity). Malkki et al. (16) found extensive diversity for microsatellite alleles on the 8.1 AH in a study in which haplotype frequencies were determined for unrelated individuals rather than from family data (16). Their index of “haplotype-specific heterozygosity” was >0.20 for 4 of 12 microsatellites located between HLA-A and HLA-DQB1. Using the same index as a measure of SNP diversity for this region, we found that only 1 of 384 consecutive SNPs had a haplotype-specific heterozygosity >0.2. These differences could reflect imprecision in the estimation of haplotype frequencies from unrelated individuals, a higher mutation rate for microsatellites, or demographic differences in the populations surveyed.

The factors that lead to the extended conservation of the 8.1 AH are currently unknown, but this extended conservation could be due to natural selection, recombination suppression, or demographic factors such as population bottlenecks, genetic drift, or migration and admixture (1720). The high frequency and extended length of the haplotype are key characteristics of recent positive selection, in which the frequency of a selectively favored allele increases rapidly over a period too short for the surrounding haplotype to become disrupted by recombination (21). The most credible example of recent positive selection is a common extended (∼1 Mb) haplotype carrying alleles associated with lactase persistence, a phenotype that may have become advantageous with the relatively recent introduction of dairy farming (22). Interestingly, the 8.1 AH was not detected in a recent global analysis of long-range linkage disequilibrium (LD) across the MHC (14). In that study, the only indications of extended LD involved a 540-kb haplotype associated with DR2 (DRB1*1501). Their inability to detect the more extensive conservation of the 8.1 AH emphasizes the need to account for prior evidence for HLA-defined ancestral haplotypes in future population genetic analyses of the MHC.

Recombination suppression is another intriguing hypothesis for explaining the extensive conservation of the 8.1 AH, particularly in light of evidence that long-range LD may not be restricted to common MHC haplotypes (17). The MHC is characterized by remarkable sequence diversity, variable haplotype lengths, and differences in gene organization (23). Sequence diversity and structural differences between homologous chromosomes may disrupt the pairing and alignment that is essential for cross overs to occur (19). Sequence heterology that inhibits crossing over could also explain the observations of greater differences in recombination rates between siblings who share one MHC haplotype compared with siblings who share two MHC haplotypes (24).

Our results demonstrating the extended length and remarkable conservation of the 8.1 AH have immediate implications for identifying specific genes and alleles that contribute to MHC-linked susceptibility to type 1 diabetes. In particular, our results imply that individuals carrying the 8.1 AH are essentially uninformative for assessing the association of variants that lie within the region of conservation with type 1 diabetes. Furthermore, the extended 8.1 AH may have a confounding effect in allelic association studies, resulting in misleading conclusions about diabetes susceptibility alleles. Data for association studies might be analyzed with and without the inclusion of the 8.1 AHs to assess for confounding effects. Nonetheless, our SNP data are important in providing a means of identifying individuals with recombinant fragments of the 8.1 AH for the identification of specific fragments that show the strongest association with disease (2). TRIMHAP (trimmed haplotype analysis for analyzing portions of extended haplotypes) is a free program written by R.B. Martin that might help with the identification of disease-associated fragments of the 8.1 AH (25). Further investigations in which the 8.1 AH and its recombinant fragments are characterized more definitively will be important for future association studies of MHC-linked susceptibility to type 1 diabetes.

FIG. 1.

Each bar represents the location of each of the 656 SNPs genotyped in relation to representative genes in the MHC gene and distance (Mb) from the telomere. The arrows represent the centromeric and telomeric ends of the remarkable region of conservation.

FIG. 2.

DR3/DR3 homozygotes (n = 13) are shown on the left and DR4/DR4 homozygotes (n = 11) on the right, with HLA-A and -B alleles identified at the top of each column (see key). The arrows below the columns indicate individuals that are homozygous for DRB1*0401-DQ8. The length of each column spans the 4.8-Mb MHC region evaluated with the 656 SNPs. Each of the 656 evenly spaced rows represents one SNP locus. Highlighted rows in each column represent heterozygous genotypes.

FIG. 3.

The left three groups depict SNP results from all DR3 haplotypes (n = 60) stratified by 8.1 AH haplotypes (n = 31); HLA-B8-DR3, non-A1 haplotypes (n = 16); and HLA-DR3, non-B8 haplotypes (n = 13), substratified by diabetic and anti-islet autoantibody status. The two panels to the right depict SNP results from non-DR3 haplotypes (n = 7) stratified by an HLA-A1-B8-DR4 haplotype (n = 1) and by HLA-A1-non-DR3, non-B8 haplotypes (n = 6). The lower frequency allele (row) for each SNP along each haplotype column is highlighted.

Acknowledgments

This work was supported by the National Institutes of Health (DK32083, DK32493, and DK057538) Autoimmunity Prevention Center (AI50964), the Diabetes Endocrine Research Center (P30 DK57516), Clinical Research Centers (MO1 RR00069 and MO1 RR00051), the Immune Tolerance Network (AI15416), the American Diabetes Association, the Juvenile Diabetes Research Foundation, and the Children’s Diabetes Foundation.

Footnotes

  • Additional information for this article can be found in an online appendix at http://diabetes.diabetesjournals.org.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted January 23, 2006.
    • Received September 29, 2005.

REFERENCES

| Table of Contents